newsfilter
← Earnings
Earnings Releases·

Curis — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $8.1 million ($1.94 per share) for Q3 2026, an improvement from $7.7 million ($9.86 per share) in Q3 2025; R&D expenses decreased to $5.6 million for the quarter from $6.4 million in the prior year period.
  • Generated zero revenue for the quarter and nine months ended September 30, 2026, following the sale of Erivedge royalties in Q4 2025, compared to $3.2 million and $8.3 million respectively in 2025.
  • Cash and cash equivalents stood at $5.0 million as of September 30, 2026; combined with $7.5 million in net proceeds from an October 2026 private placement, operations are funded into Q1 2027, though the company lacks sufficient cash to support operations for the next 12 months.
  • Clinical progress includes 12 patients enrolled in the TakeAim CLL study with initial data expected in December 2026, and updated data showing 100% ORR in evaluable BTK-naïve PCNSL patients; the company plans to continue AML development pending additional funding.
  • The company faces substantial risks regarding its ability to secure future funding for regulatory approval and commercialization, alongside potential risks to Nasdaq listing status and regulatory approvals.
Company
CURIS INC
Sector
Healthcare
Industry
Biotechnology